Tango Therapeutics (TNGX) Income towards Parent Company (2020 - 2026)

Tango Therapeutics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$45.5 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 14.14% year-over-year to -$45.5 million; the TTM figure through Mar 2026 stood at -$107.2 million (up 18.93% YoY), while the FY2025 annual figure was -$101.6 million, up 22.03% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$45.5 million, down from -$38.7 million in the prior quarter.
• The five-year high for Income towards Parent Company was $15.9 million in Q3 2025, with the low at -$45.5 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$29.1 million (2022), against an average of -$28.7 million.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company sank 453.26% in 2022, then surged 154.46% in 2025.
• Tango Therapeutics' Income towards Parent Company stood at -$29.1 million in 2022, then declined by 5.58% to -$30.7 million in 2023, then declined by 22.59% to -$37.7 million in 2024, then declined by 2.86% to -$38.7 million in 2025, then decreased by 17.46% to -$45.5 million in 2026.
• Business Quant data shows TNGX's Income towards Parent Company at -$45.5 million in Q1 2026, -$38.7 million in Q4 2025, and $15.9 million in Q3 2025.